Glob­al reach: The top 25 bio­phar­ma com­pa­nies in the world

Every­one likes to see a quick up­date on the list of the top com­pa­nies in the in­dus­try, and the lat­est break­down on big bio­phar­ma from Glob­al­Da­ta marked an op­por­tu­ni­ty I’m not go­ing to let pass.

Of note, the da­ta out­fit flagged the de­but of a Chi­nese com­pa­ny in the top 25 list. Chances are, we’ll be see­ing oth­ers join it as the in­dus­try un­der­goes a tidal shift to­ward Asia.

Oth­er high­lights in­clude a sig­nif­i­cant drop in mar­ket cap for Cel­gene $CELG as it lost fa­vor with in­vestors and now tries to win some mar­ket re­spect back.

For those of you who like com­par­isons, you would have to add the top 4 com­pa­nies on the list — the glob­al play­ers J&J, Pfiz­er, Roche and No­var­tis — to come up with one com­pa­ny big enough to ri­val Ap­ple’s $1 tril­lion mar­ket cap.

We did slight­ly re­arrange this list to in­clude a chart with up­dat­ed mar­ket caps, so you could give it all some care­ful thought. Add them all up, and the sum of the 25 parts comes to $2.9 tril­lion. The dis­tance from top to bot­tom marks a Grand Canyon of fi­nan­cial scale and reach. But what’s in­ter­est­ing is how this list could change in the next 5 years.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA